CEMIPLIMAB*
PD-1 Antibody
Cancer
A POWERFUL RESEARCH AND
DEVELOPMENT ENGINE
Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.
-
Phase 1 Trials
REGN3767
LAG-3 AntibodyCancerREGN1979
CD20xCD3 AntibodyCancerREGN4018*
MUC16xCD3 AntibodyCancerREGN4659
CTLA4 AntibodyCancerREGN5458*
BCMAxCD3 AntibodyCancerREGN3048-3051
Middle East Respiratory Coronavirus AntibodyMERS-CoV infectionREGN4461
LEPR AntibodyLipodystrophy and obesityREGN5713-5714-5715
Betv1 AntibodyBirch Allergy -
Phase 2 Trials
CEMIPLIMAB*
PD-1 AntibodyBasal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC)REGN1979CD20xCD3 AntibodyRelapsed / refractory follicular lymphomaDUPILUMAB*
IL-4R AntibodyGrass allergy, peanut allergySARILUMAB*
IL-6R AntibodyPolyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritisREGN1908-1909
Fel d 1 AntibodyCat allergyREGN3500*
IL-33 AntibodyAsthma, chronic obstructive pulmonary disease (COPD), atopic dermatitisREGN5069
GFRα3 AntibodyOsteoarthritis knee painGARETOSMAB
Activin A AntibodyFibrodysplasia Ossificans Progressiva (FOP)EVINACUMAB
ANGPTL-3 AntibodyRefractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemiaPOZELIMAB
C5 AntibodyParoxysmal nocturnal hemoglobinuria -
Phase 3 Trials
AFLIBERCEPTVEGF-TrapNon-proliferative diabetic retinopathy (NPDR) without DMEALIROCUMAB*
PCSK9 AntibodyHomozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatricsCEMIPLIMAB*
PD-1 AntibodyNon-small cell lung cancer, cervical cancerREGN-EB3
Ebola Virus AntibodyEbola virus infectionDUPILUMAB*
IL-4R AntibodyAtopic dermatitis in pediatrics, asthma in pediatric, eosinophilic esophagitis, COPDSARILUMAB*
IL-6R AntibodyPolymyalgia rheumatica, giant cell arteritisEVINACUMAB
ANGPTL-3 AntibodyHomozygous familial hypercholesterolemia (HoFH)FASINUMAB?
NGF AntibodyChronic pain from osteoarthritis of the knee or hip
Trials Footnotes
* in collaboration with Sanofi
? in collaboration with Teva and Mitsubishi Tanabe
This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.